Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioCorRx (BICX) Non Operating Income (2016 - 2025)

BioCorRx's Non Operating Income history spans 11 years, with the latest figure at $1.1 million for Q3 2025.

  • For Q3 2025, Non Operating Income rose 675.05% year-over-year to $1.1 million; the TTM value through Sep 2025 reached $1.2 million, up 969.93%, while the annual FY2024 figure was -$89597.0, 617.72% down from the prior year.
  • Non Operating Income for Q3 2025 was $1.1 million at BioCorRx, up from $36644.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $1.1 million in Q3 2025 and bottomed at -$268771.0 in Q1 2024.
  • The 5-year median for Non Operating Income is $45729.0 (2023), against an average of $95171.2.
  • The largest annual shift saw Non Operating Income skyrocketed 3807.1% in 2022 before it tumbled 741.06% in 2023.
  • A 5-year view of Non Operating Income shows it stood at $131403.0 in 2021, then crashed by 82.63% to $22821.0 in 2022, then crashed by 741.06% to -$146297.0 in 2023, then rose by 29.67% to -$102893.0 in 2024, then soared by 1205.12% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for BICX's Non Operating Income are $1.1 million (Q3 2025), $36644.0 (Q2 2025), and $86182.0 (Q1 2025).